Routine echocardiography screening for asymptomatic left ventricular dysfunction in childhood cancer survivors: A model-based estimation of the clinical and economic effects

Annals of Internal Medicine

Volumn 160, Issue 10, 2014, Pages 661-671

  Yeh, Jennifer M ^a   Nohria, Anju ^b   Diller, Lisa ^c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADOLESCENT; ADULT; ARTICLE; ASYMPTOMATIC DISEASE; CANCER INCIDENCE; CANCER SURVIVOR; CARDIOVASCULAR RISK; CHILD; CHILDHOOD CANCER; CLINICAL ASSESSMENT; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; ECHOCARDIOGRAPHY; ECONOMIC ASPECT; FEMALE; HEALTH CARE COST; HEART LEFT VENTRICLE FAILURE; HUMAN; LIFE EXPECTANCY; LIFESPAN; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; ONSET AGE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SCREENING; SENSITIVITY ANALYSIS; SIMULATION; SYSTOLIC HEART FAILURE;

ADOLESCENT; ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHILD; COHORT STUDIES; COST-BENEFIT ANALYSIS; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MODELS, THEORETICAL; NEOPLASMS; QUALITY-ADJUSTED LIFE YEARS; SENSITIVITY AND SPECIFICITY; SURVIVORS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84901286409     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M13-2266     Document Type: Article

References (46)

1. de Moor JS, Mariotto AB, Parry C, Alfano CM, Padgett L, Kent EE, et al. Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care. Cancer Epidemiol Biomarkers Prev. 2013;22:561-70. [PMID: 23535024]
2. Mertens AC, Yasui Y, Neglia JP, Potter JD, Nesbit ME Jr., Ruccione K, et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J Clin Oncol. 2001;19:3163-72. [PMID: 11432882]
3. Moller TR, Garwicz S, Barlow L, Falck Winther J, Glattre E, Olafsdottir G, et al; Association of the Nordic Cancer Registries. Decreasing late mortality among five-year survivors of cancer in childhood and adolescence: a populationbased study in the Nordic countries. J Clin Oncol. 2001;19:3173-81. [PMID: 11432883]
4. Cardous-Ubbink MC, Heinen RC, Langeveld NE, Bakker PJ, Voûte PA, Caron HN, et al. Long-term cause-specific mortality among five-year survivors of childhood cancer. Pediatr Blood Cancer. 2004;42:563-73. [PMID: 15127410]
5. MacArthur AC, Spinelli JJ, Rogers PC, Goddard KJ, Abanto ZU, McBride ML. Mortality among 5-year survivors of cancer diagnosed during childhood or adolescence in British Columbia, Canada. Pediatr Blood Cancer. 2007;48:460-7. [PMID: 16767717]
6. Inskip PD, Curtis RE. New malignancies following childhood cancer in the United States, 1973-2002. Int J Cancer. 2007;121:2233-40. [PMID: 17557301]
7. Mertens AC, Liu Q, Neglia JP, Wasilewski K, Leisenring W, Armstrong GT, et al. Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2008;100: 1368-79. [PMID: 18812549]
8. Green DM, Hyland A, Chung CS, Zevon MA, Hall BC. Cancer and cardiac mortality among 15-year survivors of cancer diagnosed during childhood or adolescence. J Clin Oncol. 1999;17:3207-15. [PMID: 10506620]
9. Lawless SC, Verma P, Green DM, Mahoney MC. Mortality experiences among 15-year survivors of childhood and adolescent cancers. Pediatr Blood Cancer. 2007;48:333-8. [PMID: 16453299]
10. Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D'Agostino RB, Kannel WB, et al; Framingham Heart Study. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 2002;106:3068-72. [PMID: 12473553]
11. Mulrooney DA, Yeazel MW, Kawashima T, Mertens AC, Mitby P, Stovall M, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ. 2009;339:b4606. [PMID: 19996459]
12. van der Pal HJ, van Dalen EC, van Delden E, van Dijk IW, Kok WE, Geskus RB, et al. High risk of symptomatic cardiac events in childhood cancer survivors. J Clin Oncol. 2012;30:1429-37. [PMID: 22473161]
13. Children's Oncology Group. Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancer Survivors. Version 3.0.
14. Accessed at www.survivorshipguidelines.org on 16 January 2014.
15. Shankar SM, Marina N, Hudson MM, Hodgson DC, Adams MJ, Landier W, et al; Cardiovascular Disease Task Force of the Children's Oncology Group. Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children's Oncology Group. Pediatrics. 2008;121:e387-96. [PMID: 18187811]
16. Armstrong GT, Plana JC, Zhang N, Srivastava D, Green DM, Ness KK, et al. Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging. J Clin Oncol. 2012;30:2876-84. [PMID: 22802310]
17. Lipshultz SE, Colan SD. Cardiovascular trials in long-term survivors of childhood cancer [Editorial]. J Clin Oncol. 2004;22:769-73. [PMID: 14990630]
18. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making. 1983;3:419-458. [PMID: 6668990]
19. Sonnenberg FA, Beck Jr. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322-38. [PMID: 8246705]
20. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Pr; 1996.
21. Neumann PJ, Sandberg EA, Bell CM, Stone PW, Chapman RH. Are pharmaceuticals cost-effective? A review of the evidence. Health Aff (Millwood). ;19:92-109. [PMID: 10718025]
22. National Heart, Lung, and Blood Institute. Incidence and Prevalence: 2006 Chart Book on Cardiovascular and Lung Diseases. Bethesda, MD: National Heart, Lung, and Blood Institute; 2006. Accessed at www.nhlbi.nih.gov/resources/docs/ 06a-ipchtbk.pdf on 24 March 2014.
23. Wang TJ, Evans JC, Benjamin EJ, Levy D, LeRoy EC, Vasan RS. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation. 2003;108:977-82. [PMID: 12912813]
24. Lipshultz SE, Sleeper LA, Towbin JA, Lowe AM, Orav EJ, Cox GF, et al. The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med. 2003;348:1647-55. [PMID: 12711739]
25. Centers for Disease Control and Prevention. CDC WONDER On-line Database, compiled from Compressed Mortality File CMF 1968-1988, Series 20, No. 2A, 2000 and CMF 1989-1998, Series 20, No. 2E, 2003. Accessed at http://wonder.cdc.gov/ cmf-icd9.html on 24 March 2009.
26. Schocken DD, Arrieta MI, Leaverton PE, Ross EA. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol. 1992;20:301-6. [PMID: 1634664]
27. Yeh JM, Nekhlyudov L, Goldie SJ, Mertens AC, Diller L. A model-based estimate of cumulative excess mortality in survivors of childhood cancer. Ann Intern Med. 2010;152:409-17, W131-8. [PMID: 20368646]
28. Mant J, Doust J, Roalfe A, Barton P, Cowie MR, Glasziou P, et al. Systematic review and individual patient data meta-Analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. Health Technol Assess. 2009;13:1-207, iii. [PMID: 19586584]
29. Exner DV, Dries DL, Waclawiw MA, Shelton B, Domanski MJ. Betaadrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol. 1999;33:916-23. [PMID: 10091816]
30. Hanmer J, Lawrence WF, Anderson JP, Kaplan RM, Fryback DG. Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med Decis Making. 2006;26:391-400. [PMID: 16855127]
31. Gohler A, Geisler BP, Manne JM, Kosiborod M, Zhang Z, Weintraub WS, et al. Utility estimates for decision-Analytic modeling in chronic heart failure-health states based on New York Heart Association classes and number of rehospitalizations. Value Health. 2009;12:185-7. [PMID: 18647251]
32. Centers for Medicare & Medicaid Services. Research, Statistics, Data & Systems; 2012. Accessed at www.cms.gov/Research-Statistics-Data-And- Systems/Research-Statistics-Data-And-Systems.html on 1 February 2013.
33. Truven Health Analytics. Micromedex Solutions. Red Book. Accessed at http://micromedex.com/redbook on 28 February 2013.
34. Bureau of Labor Statistics. Occupational Employment and Wages. 2012. Accessed at http://stat.bls.gov/oes/home.htm on 15 February 2013.
35. Owan TE, Redfield MM. Epidemiology of diastolic heart failure. Prog Cardiovasc Dis. 2005;47:320-32. [PMID: 16003647]
36. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr., Drazner MH, et al; American College of Cardiology Foundation. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62:e147-239. [PMID: 23747642]
37. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362:767-71. [PMID: 13678869]
38. Silber JH, Cnaan A, Clark BJ, Paridon SM, Chin AJ, Rychik J, et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol. 2004;22:820-8. [PMID: 14990637]
39. Sieswerda E, van Dalen EC, Postma A, Cheuk DK, Caron HN, Kremer LC. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer. Cochrane Database Syst Rev. 2011:CD008011. [PMID: 21901716]
40. Foerster SR, Canter CE. Pediatric heart failure therapy with betaadrenoceptor antagonists. Paediatr Drugs. 2008;10:125-34. [PMID: 18345722]
41. Shaddy RE, Boucek MM, Hsu DT, Boucek RJ, Canter CE, Mahony L, et al; Pediatric Carvedilol Study Group. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA. 2007;298:1171-9. [PMID: 17848651]
42. Lipshultz SE, Adams MJ, Colan SD, Constine LS, Herman EH, Hsu DT, et al; American Heart Association Congenital Heart Defects Committee of the Council on Cardiovascular Disease in the Young, Council on Basic Cardiovascular Sciences, Council on Cardiovascular and Stroke Nursing, Council on Cardiovascular Radiology and Intervention, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Council on Nutrition, Physical Activity and Metabolism. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation. 2013;128:1927-95. [PMID: 24081971]
43. Heidenreich PA, Gubens MA, Fonarow GC, Konstam MA, Stevenson LW, Shekelle PG. Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. J Am Coll Cardiol. 2004;43:1019-26. [PMID: 15028361]
44. Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, Gelber RD, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23:2629-36. [PMID: 15837978]
45. Redfield MM, Jacobsen SJ, Burnett JC Jr., Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003; 289:194-202. [PMID: 12517230]
46. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-53. [PMID: 10639539]